Duloxetine Delayed-Release Capsules USP, 20 mg, packaged in a) 30 Unit Doses (3x10 blister packs)...

FDA Recall #D-0212-2025 — Class II — January 13, 2025

Recall #D-0212-2025 Date: January 13, 2025 Classification: Class II Status: Terminated

Product Description

Duloxetine Delayed-Release Capsules USP, 20 mg, packaged in a) 30 Unit Doses (3x10 blister packs) NDC 0904-7043-04 and b) 100 Unit Doses (10x10 blister packs) NDC 0904-7043-61, Rx only, Packaged and Distributed by: Major Pharmaceuticals, Indianapolis, IN 46268 USA.

Reason for Recall

CGMP Deviations: presence of Nitrosamine Drug Substances Related Impurity (NDSRI), N-Nitroso-Duloxetine above the FDA recommended acceptable intake limit

Recalling Firm

The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories — La Vergne, TN

Classification

Class II — May cause temporary or medically reversible adverse health consequences.

Product Type

Drugs

Product Quantity

a) 6408 boxes and b)1488 boxes

Distribution

Nationwide within the United States

Code Information

Lot #: a) N01530, Exp. Date 01/2025; b) N01540, Exp. Date. 01/2025

Status

Terminated

Voluntary / Mandated

Voluntary: Firm initiated